Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04373551 · ClinicalTrials.gov registry record · NA

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

A NA study of HIV-infection/AIDS, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
67
Enrollment target
1
Study location

NCT04373551 is a NA study of HIV-infection/AIDS that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 67 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04373551, a NA study of HIV-infection/AIDS, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
67 participants
Enrollment target
1
Study location

Study Summary

The objective of this application is to increase PrEP uptake among women vulnerable to HIV acquisition in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama. The investigators will use a mixed-methods approach to adapt and pilot test a patient-provider communication tool from the Centers for Disease Control and Prevention (CDC) PrEP toolkit that focuses on the first three steps of the PrEP cascade (e.g., recognizing HIV risk, identifying as a PrEP candidate, and interested in PrEP) to increase PrEP uptake via referrals to local PrEP clinics.

Conditions Studied

Interventions

  • BEHAVIORAL Cultural adaptation of a patient-provider communication tool

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2022-03-07
Est. Completion 2024-06-30
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT04373551

The ClinicalTrials.gov registry entry for NCT04373551 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV-infection/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Cultural adaptation of a patient-provider communication tool is the first listed.

NCT04373551 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT04373551 about?

NCT04373551 is a clinical study titled "WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)". The objective of this application is to increase PrEP uptake among women vulnerable to HIV acquisition in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama. The investigators will use a mixed-methods approach to adapt and pilot test a...

What is the current status of trial NCT04373551?

This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2022-03-07. Estimated completion is 2024-06-30.

What conditions does trial NCT04373551 study?

This clinical trial studies the following conditions: HIV-infection/AIDS.

What interventions are being tested in trial NCT04373551?

The interventions under investigation include: Cultural adaptation of a patient-provider communication tool (BEHAVIORAL).

Who is sponsoring clinical trial NCT04373551?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04373551 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.